Viewing nowCombinationEmpagliflozin/Metformin Extended-Release Tablets 25/1000 mg (Empagliflozin, Metformin)
Empagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.

MFDS item code 202501578 · Approved 2025.06.26 · Insurance code 654006250
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to dietary and exercise therapy to improve blood sugar control in adults with type 2 diabetes through the combined administration of empagliflozin and metformin. Clinical trial information should be referenced to manage the occurrence of cardiovascular events cautiously, especially in patients whose blood sugar is inadequately controlled and who have established cardiovascular disease. This medication is effective in controlling blood sugar levels and aids in managing type 2 diabetes.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the feces. It is not known whether the substance excreted in the feces contains the active ingredient of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). For patients whose blood glucose cannot be adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). Special populations Renal impairment Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this drug may be used with the following adjustment to the metformin hydrochloride dose. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. Older adults In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.
This medication helps control blood sugar levels and is used in the treatment of diabetes. This medication may rarely cause lactic acidosis, which is a dangerous condition, so it should not be used in patients with impaired kidney function, severe infection, or dehydration. Additionally, caution is advised when using this medication in conjunction with insulin or other diabetes medications, as hypoglycemia may occur. Patients with moderate to severe renal impairment, acute renal issues, severe heart failure, or those undergoing certain contrast imaging tests should not use this medication. Women who are pregnant or breastfeeding and patients with severe liver or lung dysfunction should also not take this medication. This medication increases urination and can raise the risk of urinary tract infections or genital infections; any related symptoms should be discussed with a healthcare professional immediately. Long-term use may lower vitamin B12 levels; therefore, regular monitoring of blood vitamin B12 concentrations is advisable. Alcohol consumption can increase the risk of lactic acidosis, so avoid excessive drinking while taking this medication. Patients scheduled for surgery should stop taking this medication 48 hours before surgery and resume only after confirming normal renal function post-surgery. During treatment with this medication, adequate fluid intake and monitoring of the condition are essential to prevent dehydration or fluid loss. Symptoms of hypoglycemia may occur, so blood sugar levels should be monitored carefully, especially after irregular meals or vigorous exercise. This medication must be swallowed whole and should not be crushed or chewed. It is normal for the tablet coating to appear in the stool. Elderly or patients with reduced renal function may require dosage adjustments and regular renal function tests. In the case of overdose, serious side effects such as lactic acidosis may occur, and immediate medical attention is necessary, which may include hemodialysis. Finally, this medication should be stored out of reach of children and kept in its original container.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture, and keep it at room temperature between 1 and 30 degrees Celsius for safety.
Pink rectangular extended-release film-coated tablet
Bottle packaging - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.